# Orforglipron ACHIEVE-4: heart safety vs insulin glargine

Source: https://pepvault.app/research/orforglipron-achieve-4-2026

Last updated: 2026-11-17

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Research](https://pepvault.app/research) [Orforglipron](https://pepvault.app/research#orforglipron)

Randomized trial · people

# Orforglipron: heart events no worse than insulin in ACHIEVE-4

Checked against the paper November 2026 Randomized trial [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The takeaway

In adults with type 2 diabetes and high heart risk, orforglipron did not raise major heart events compared with insulin glargine over about 2 years, with more gut side effects but fewer low blood sugar episodes.

- **Kind:** Randomized trial
- **Studied in:** People
- **Number studied:** 2749
- **Published:** 2026
- **Journal:** Lancet

## What they tested

The team tested whether daily oral orforglipron is no worse than insulin glargine for major heart and blood vessel events in adults with type 2 diabetes at higher heart risk.

## How the study was done

A phase 3, randomized, open-label trial at 317 sites in 16 countries and territories. It enrolled 2749 adults with type 2 diabetes, a BMI of 25 kg/m2 or more, and established heart or chronic kidney disease, who got either once-daily oral orforglipron at the highest dose they tolerated (up to 36 mg capsule) or once-daily injected insulin glargine, with a median follow-up of 2 years.

<!--promo-->

PepVault for iPhone

## Taking orforglipron? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What they found

The main outcome was MACE-4, a combined count of heart-related death, non-fatal heart attack, non-fatal stroke, or a hospital stay for unstable angina (chest pain from poor blood flow to the heart). It occurred in 57 (4.2%) of 1358 people on orforglipron and 67 (5.0%) of 1343 on insulin glargine, a hazard ratio (relative risk over time) of 0.84 (95% CI 0.59-1.20), which met the trial's test for being no worse than insulin. Gut side effects were reported in 62.1% on orforglipron vs 14.2% on insulin glargine, and were the most common reason people stopped orforglipron, while clinically significant or severe low blood sugar occurred in 6.8% vs 19.2%. There were 19 deaths (1.4%) on orforglipron and 43 (3.2%) on insulin glargine, and all but one, in the insulin group, were judged unrelated to treatment.

## What it doesn’t show

The trial was built to show orforglipron was no worse than insulin glargine, not to show it lowers heart events, and it was open-label, so people knew which treatment they got. It only included people with type 2 diabetes and existing heart or kidney disease, and it was funded by Eli Lilly and Company.

## The paper

Klein et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial. Lancet. 2026.

- [PubMed (PMID 42815506)](https://pubmed.ncbi.nlm.nih.gov/42815506/)
- [The paper (DOI 10.1016/S0140-6736(26)01865-9)](https://doi.org/10.1016/S0140-6736%2826%2901865-9)
- [ClinicalTrials.gov (NCT05803421)](https://clinicaltrials.gov/study/NCT05803421)

## The compound

- [Orforglipron: how it works, half-life, studied range and evidence](https://pepvault.app/peptides/orforglipron)
- [Orforglipron dose guide](https://pepvault.app/lab/dosage/orforglipron)

## With this study

### Orforglipron

- [Orforglipron: the full reference](https://pepvault.app/peptides/orforglipron)
- [Orforglipron dose guide](https://pepvault.app/lab/dosage/orforglipron)

### Studies

- [Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2](https://pepvault.app/research/orforglipron-attain-2-2026)
- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026)
- [All 5 studies](https://pepvault.app/research#orforglipron)

### Compared with

- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)
- [Orforglipron vs Semaglutide (oral)](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide-oral)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)

### Tools

- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

## More studies on Orforglipron

- [Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2](https://pepvault.app/research/orforglipron-attain-2-2026) Randomized trial · people · 2026
- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026) Randomized trial · people · 2026
- [Orforglipron 36 mg: 11.2% weight loss at 72 weeks in ATTAIN-1](https://pepvault.app/research/orforglipron-attain-1-2025) Randomized trial · people · 2025
- [Orforglipron: food lowered drug exposure by 17.6% to 23.7%](https://pepvault.app/research/orforglipron-ma-2024) Clinical trial · people · 2024
- [Every study on Orforglipron](https://pepvault.app/research#orforglipron)

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed November 2026. Spot an error? [feedback@pepvault.app](mailto:feedback@pepvault.app). [How we research](https://pepvault.app/guides/how-we-research). This page reports one study; it is not medical advice.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking orforglipron? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking orforglipron? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this study

### Orforglipron

- [Orforglipron: the full reference](https://pepvault.app/peptides/orforglipron)
- [Orforglipron dose guide](https://pepvault.app/lab/dosage/orforglipron)

### Studies

- [Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2](https://pepvault.app/research/orforglipron-attain-2-2026)
- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026)
- [All 5 studies](https://pepvault.app/research#orforglipron)

### Compared with

- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)
- [Orforglipron vs Semaglutide (oral)](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide-oral)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)

### Tools

- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

<!--promo-->

PepVault for iPhone

## Taking orforglipron? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## Research

- [All studies](https://pepvault.app/research)
- [Every study on Orforglipron](https://pepvault.app/research#orforglipron)

## The library

- [Orforglipron](https://pepvault.app/peptides/orforglipron)
- [Orforglipron dose guide](https://pepvault.app/lab/dosage/orforglipron)
- [The peptide reference library](https://pepvault.app/peptides)

## How we work

- [How we research](https://pepvault.app/guides/how-we-research)
- [How we check the library](https://pepvault.app/about#library)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
